Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Roll-over Study to Allow Continued Access to Ribociclib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-
- Status
- UNKNOWN
- Phase
- N/A
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
- Status
- TERMINATED
- Phase
- PHASE2
Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- NA
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC
- Status
- UNKNOWN
- Phase
- N/A
Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Fulvestrant + Neratinib In Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
- Status
- TERMINATED
- Phase
- PHASE2